MARKET WIREYahoo Finance • 15h ago
Disc Medicine (IRON) Stock Still Looks Pricey As Book Value Lags ExpectationsYahoo Finance report covering Disc Medicine Inc. (IRON) market action, institutional positioning, and fundamental catalysts.
Why IRON Stock dropped -2.41% Today — RQD Quant Desk Flash
$80.84 -2.41% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $80.34
Disc Medicine Inc. (IRON) carries a Roarable Rating of D+ (Sell) with 54/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D+ • SELL / AVOID
Cap $3.59B
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on IRON Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is IRON stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Disc Medicine Inc. (NASDAQ: IRON) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 54/100 at a spot price of $80.84 (-2.41% 1D, market cap $3.59B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 16/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 6/20. Across 1016 tracked Health Care issuers, IRON ranks #217 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does IRON compare to AMLX and XENE in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), IRON carries a Roarable D+ (54/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -27.5%. By comparison, AMLX (Amylyx Pharmaceuticals Inc.) holds a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $3.62B) and XENE (Xenon Pharmaceuticals Inc.) posts a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $3.62B). Among the 5-stock peer group, ACAD leads on earnings multiple (9.1x) while OGN leads on capital efficiency (24.9% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for IRON?
▼
Per IRON's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001816736), Disc Medicine Inc. generated $0 in revenue, -$212.2M in net income, and -$181.3M in free cash flow against $806.9M in total assets and $30.2M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $80.34 (-0.62%)🧬 Dilution Drag (+1.64% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 54/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.7% avg 90D alpha vs SPY • 51.0% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D+
JEV AI Jury Split (Battleground)
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D · Rk C-
Each axis scored 0–20
12M PRICE TARGET CONE-1.8% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for IRON)Realized 20D OHLCV Swing Band: ±10.7%
Deterministic 5-Pillar Attribution (54/100 Composite)
🔍 WHY IRON SCORES 54/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+16/20 pts (30% of score)
20D Institutional Volume Accumulation (±10.7% realized swing band)
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+14/20 pts (26% of score)
Altman Z-Score 26.00 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 5/9
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution6/20 pts (-14 pt drag)
Dilution Drag (+1.64% YoY Shares) & executive Form 4 sales trim 14 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$55.74+36.3% Next Q
46
Q2 (-2Q)Grade D$76.00+9.5% Next Q
49
Q3 (-1Q)Grade C-$83.20-2.8% Next Q
51
CurrentGrade D+$80.84-0.7% Hist 90D α
54
Trajectory: D (46) → D+ (54)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a IRON Turnaround Squeeze
While IRON currently carries a cautious 54/100 (D+) rating due to Insider Conviction & Share Dilution (6/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Big institutional funds and options desks are actively positioning on the bullish side.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($71.43) and Max Pain ($84.88) forces dealer call-delta covering toward $104.48.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.64% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $IRON• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “IRON Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why IRON Stock dropped -2.41% Today — RQD Quant Desk Flash
Disc Medicine Inc. (IRON) dropped -2.41% to $80.84, trading at 69% of its 52-week range ($40 – $99.5). Stretched risk/reward at current multiples (-28% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 69% of its 52-week range ($40 – $99.5) with RSI-14 at 62.4 (BULLISH MOMENTUM).
- ▸Volatility Profile: Historical 20-day realized swing band of ±10.7% around $80.84 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D+ (Sell) backed by 0% gross margin and $0 annual free cash flow.
Live IRON Headlines & Catalysts
MARKET WIREWilmerHale • 18h ago
WilmerHale Advises Underwriters in Disc Medicine’s Upsized $450 Million Public OfferingWilmerHale report covering Disc Medicine Inc. (IRON) market action, institutional positioning, and fundamental catalysts.
MARKET WIRESeeking Alpha • 21h ago
Disc Medicine: Second To Market, Priced Like It's First (NASDAQ:IRON)Seeking Alpha report covering Disc Medicine Inc. (IRON) market action, institutional positioning, and fundamental catalysts.
CATALYSTTradingView • 1d ago
Disc Medicine stock soars: take profit or buy into strength?TradingView report covering Disc Medicine Inc. (IRON) market action, institutional positioning, and fundamental catalysts.
CATALYSTYahoo Finance • 1d ago
Disc Medicine Stock Jumps After Phase 3 Trial Success And FDA Refiling PlanYahoo Finance report covering Disc Medicine Inc. (IRON) market action, institutional positioning, and fundamental catalysts.
CATALYSTGuruFocus • 1d ago
Disc Medicine (IRON) Shares Surge 30% Ahead of Phase 3 APOLLO TrGuruFocus report covering Disc Medicine Inc. (IRON) market action, institutional positioning, and fundamental catalysts.
CATALYSTInvesting.com • 1d ago
Disc Medicine stock price target raised to $115 by Truist on drug outlookInvesting.com report covering Disc Medicine Inc. (IRON) market action, institutional positioning, and fundamental catalysts.
RISK WATCHMarketBeat • 1d ago
Disc Medicine (NASDAQ:IRON) Stock Gets Downgrade from Wall Street ZenMarketBeat report covering Disc Medicine Inc. (IRON) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo • 12d ago
Disc Medicine Delivers Promise For Patients with Sunlight Sensitivity In Successful Pivotal StudyDisc Medicine Inc. on Monday reported positive topline results from its APOLLO Phase 3 trial evaluating bitopertin for erythropoietic protoporphyria, or EPP, including X-linked protoporphyria, or XLP. EPP and XLP are cha
MARKET WIREYahoo • 13d ago
Disc Medicine Announces Pricing of $450 Million Upsized Public Offering of Common StockWATERTOWN, Mass., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments f
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring IRON)
- ✓Walkthrough of IRON's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
IRON // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +19.52%📐 HORIZONTAL RANGE
2026-11-03O $82.84H $82.84L $80.84C $80.84VOL 685.0K
RES: $85.12SUP: $51.21SMA50: $71.43SMA200: $70.84
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
IRON Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
13.5%/yr Implied 5Y Growth
vs. +16.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on IRON today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for IRON. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for IRON today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (IRON)
Health Care Rank #217 of 1016
⚔️ AMLX vs IRON Full Matrix →
1. Head-to-Head Health Care Peer Comparison (IRON vs. AMLX, XENE, ACAD, OGN)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Disc Medicine Inc. (IRON) ranks #217 by composite RQD confidence (54/100, grade D+) and #192 by equity capitalization ($3.59B). Within this direct 5-issuer industry benchmark cohort, ACAD leads on earnings valuation at 9.1x trailing P/E, while OGN leads on capital efficiency and profitability with 24.9% ROIC and 53.3% gross margin. OGN currently holds the highest overall quantitative score in the immediate peer group at 70/100 (B-) compared with IRON at 54/100 (D+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| IRON
ACTIVE
Disc Medicine Inc. | D+ | 54/100 | — | — | -27.5% | -2.41% | $3.59B | Benchmark Subject |
| AMLX Amylyx Pharmaceuticals Inc. | D- | 39/100 | — | — | -35.0% | +0.63% | $3.62B | /amlx-vs-iron → |
| XENE Xenon Pharmaceuticals Inc. | D- | 37/100 | — | — | -35.0% | -0.35% | $3.62B | /xene-vs-iron → |
| ACAD ACADIA Pharmaceuticals Inc. | D | 49/100 | 9.1x | 91.7% | 7.9% | -0.82% | $3.55B | /acad-vs-iron → |
| OGN Organon & Co. | B- | 70/100 | 19.4x | 53.3% | 24.9% | +0.22% | $3.63B | /ogn-vs-iron → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001816736In its most recent audited fiscal period (FY2025, filed 2025-12-31), Disc Medicine Inc. (IRON) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$212.2M, operating cash flow of -$180.4M, and free cash flow of -$181.3M (-92.0% YoY). On the balance sheet, IRON closed FY2025 with $806.9M in total assets against $30.2M in total debt (Altman Z-Score: 26.00, Piotroski F-Score: 5/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$212.2M | -$180.4M | -$181.3M | $806.9M | $30.2M |
| FY2024 (FY) | 2024-12-31 | $0 | -$109.4M | -$93.9M | -$94.4M | $496.8M | $23.9M |
| FY2023 (FY) | 2023-12-31 | $0 | -$76.4M | -$73.5M | -$73.5M | $2.02B | $473.3M |
3. IRON Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs IRON stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Disc Medicine Inc. (NASDAQ: IRON) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 54/100 at a spot price of $80.84 (-2.41% 1D, market cap $3.59B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 16/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 6/20. Across 1016 tracked Health Care issuers, IRON ranks #217 in composite RQD confidence.
How does IRON compare to AMLX and XENE in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), IRON carries a Roarable D+ (54/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -27.5%. By comparison, AMLX (Amylyx Pharmaceuticals Inc.) holds a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $3.62B) and XENE (Xenon Pharmaceuticals Inc.) posts a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $3.62B). Among the 5-stock peer group, ACAD leads on earnings multiple (9.1x) while OGN leads on capital efficiency (24.9% ROIC).
What are the biggest fundamental strengths and SEC risk factors for IRON?
Per IRON's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001816736), Disc Medicine Inc. generated $0 in revenue, -$212.2M in net income, and -$181.3M in free cash flow against $806.9M in total assets and $30.2M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is IRON trading relative to its 50-day, 200-day, and 52-week technical levels?
IRON last traded at $80.84 (-2.41% on volume of 685,006 shares), positioning the stock +13.17% above its 50-day simple moving average ($71.43) and +14.12% above its 200-day simple moving average ($70.84). Across its 52-week range of $40.00 to $99.50, IRON sits at the 68.6% percentile with a 14-day RSI of 62.4 (BULLISH MOMENTUM) and an implied next-earnings move of ±10.7% ($72.19 to $89.49).
IRON Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is IRON stock moving today?
Why IRON Stock dropped -2.41% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-28% return on capital) under elevated 10-year interest-rate pressure.
ROARABLE RATING BRIEF • RQD 54/100 (D+)
✓ STAGE-C NUMBER FIREWALL VERIFIED
IRON — Disc Medicine Inc.: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:23:03Z
Roarable Rating Brief: What This Means to a Prospective Investor
The Roarable RQD rating assigns IRON a score of 54 out of 100, a letter grade of D+, and a verdict label of "Roarable Sell — Weak Fundamentals / Trim." Across the five pillars, per the Roarable RQD rating:
- Fundamental Cash Engine: 8 / 20. The pillar cites ROIC of -27.5% and an FCF yield of -4.93%. For a prospective investor, this is the weakest area: the company is currently not generating a cash return on invested capital or positive free cash flow, so value must rest on future cash generation rather than present earnings.
- Whale 13F Flow: 16 / 20. Scored on institutional accumulation and options positioning. This is a relative strength, suggesting larger institutional holders have been building or maintaining exposure, though the source data does not itemize those holdings.
- Insider Conviction: 6 / 20. Scored on SEC Form 4 and Congressional PTR cluster flow. The low score indicates limited insider-side buying conviction in the source data.
- Macro Regime Fit: 10 / 20. Cites Beta of 0.9 and sector sensitivity. A beta below 1.0 implies somewhat lower sensitivity to broad market moves than the market average, but the pillar score is only moderate.
- Forensic Balance Sheet: 14 / 20. Cites Altman Z of 26, Piotroski F of 5/9, and Debt/Equity of 0.04. The balance sheet is the strongest structural support: leverage is very low and the Altman Z is high, though the Piotroski score is mid-range.
Investor implications: upside depends largely on whether the pipeline and catalysts (see news section) translate into future cash generation, which the current cash-engine pillar does not yet show. Valuation tradeoffs are significant: the stock trades at a forward P/E of 20 against negative trailing EPS of -4.78, meaning the market is pricing in earnings that do not yet exist in reported results. Low leverage limits solvency risk, but the negative cash-flow trend and the recent equity raise described in the news wire are key considerations.
Business
Disc Medicine Inc. is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry, per the company profile. The source data does not describe its products, customers, or revenue model. Reported revenue is $0.0M in each listed period, per the SEC financials, indicating no reported revenue in the source data. Market capitalization is $3.7B per the profile.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $0.0M | $-236.0M | $-212.2M | N/A | $-181.3M | $91.1M | $30.2M |
| FY 2024 | $0.0M | $-129.7M | $-109.4M | N/A | $-94.4M | $192.4M | $23.9M |
| FY 2023 | $0.0M | $-91.1M | $-76.4M | N/A | $-73.5M | N/A | $473.3M |
Per the SEC financials, operating and net losses widened from FY 2023 to FY 2025, and free cash flow was negative in every period. Per the market data, gross margin is 0%, operating margin is -22.9%, and net margin is -20.6%, while ROIC is -27.5%. The Altman Z-Score of 26 and Piotroski F-Score of 5/9 are cited in the Roarable RQD rating. Debt/Equity of 0.04 per the RQD rating, and reported cash fell from $192.4M to $91.1M over FY 2024–FY 2025 while debt rose from $23.9M to $30.2M, per the SEC financials. Debt was $473.3M in FY 2023, per the SEC financials.
Recent Catalysts & News Wire Analysis
- Offering: A WilmerHale report describes advising underwriters on an upsized $450 Million public offering (YELLOW light, MARKET WIRE).
- Phase 3 / regulatory: Reports describe a Phase 3 trial success and an FDA refiling plan (GREEN, CATALYST), and a Phase 3 APOLLO trial ahead of which shares surged 30% (GREEN, CATALYST).
- Valuation commentary: Coverage describes the stock as still looking pricey with book value lagging expectations (YELLOW, MARKET WIRE), and as "Second To Market, Priced Like It's First" (YELLOW, MARKET WIRE).
- Trading commentary: A TradingView report asks whether to take profit or buy into strength after a sharp rise (GREEN, CATALYST).
Risk watch items: the $450 Million offering, negative operating cash flow, and valuation concerns raised in the news wire. Proprietary signals: none listed in the Butterfly Supply-Chain Graph.
Open Questions
- What specific products or pipeline assets drive the Phase 3 and FDA refiling catalysts, and what is their expected commercial timeline?
- How will the $450 Million offering's proceeds be deployed relative to the negative free cash flow reported in FY 2025?
- Why is revenue reported as $0.0M across all periods, and when is commercial revenue expected?
- Who are the institutional holders behind the 13F accumulation cited in the RQD rating?
- What explains the gap between the reported forward P/E of 20 and negative trailing EPS?
IRON Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Disc Medicine Inc. (IRON) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo Finance • 15h ago
Disc Medicine (IRON) Stock Still Looks Pricey As Book Value Lags Expectations Yahoo Finance report covering Disc Medicine Inc. (IRON) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE WilmerHale • 18h ago
WilmerHale Advises Underwriters in Disc Medicine’s Upsized $450 Million Public Offering WilmerHale report covering Disc Medicine Inc. (IRON) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Seeking Alpha • 21h ago
Disc Medicine: Second To Market, Priced Like It's First (NASDAQ:IRON) Seeking Alpha report covering Disc Medicine Inc. (IRON) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST TradingView • 1d ago
Disc Medicine stock soars: take profit or buy into strength? TradingView report covering Disc Medicine Inc. (IRON) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Yahoo Finance • 1d ago
Disc Medicine Stock Jumps After Phase 3 Trial Success And FDA Refiling Plan Yahoo Finance report covering Disc Medicine Inc. (IRON) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST GuruFocus • 1d ago
Disc Medicine (IRON) Shares Surge 30% Ahead of Phase 3 APOLLO Tr GuruFocus report covering Disc Medicine Inc. (IRON) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Investing.com • 1d ago
Disc Medicine stock price target raised to $115 by Truist on drug outlook Investing.com report covering Disc Medicine Inc. (IRON) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH MarketBeat • 1d ago
Disc Medicine (NASDAQ:IRON) Stock Gets Downgrade from Wall Street Zen MarketBeat report covering Disc Medicine Inc. (IRON) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
IRON Bull vs. Bear Conversation Board — What's Your Call at $80.84?
🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON IRON 🐻 50% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST
🎯 Target: $89.47 (+8.0%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is IRON (D+ • RQD 54/100) a Buy at $82.84?
Welcome to the IRON (Disc Medicine Inc.) Roar Pit. Current RQD Composite is 54/100 (Roarable Sell — Weak Fundamentals / Trim) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
BE BearTrap_Alert Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $67.10 (-19.0%)
Spot @ $82.84 Pump the brakes on IRON — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on IRON, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Disc Medicine Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
CA CashFlowKing Verified K Arena Trader 🐂 BULLISH
🎯 Target: $101.06 (+22.0%)
Spot @ $82.84 IRON cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on IRON, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $82.84 (52-wk range $40.00 - $99.50), any beat on forward guidance forces shorts and underweight funds to chase.